Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02028533 · ClinicalTrials.gov registry record · Phase 1
Cocaine Opioid Oxytocin Option - Limited
A Phase 1 study of Opioid Use Disorder and Cocaine Use Disorder, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT02028533: Completed Phase 1 study of Opioid Use Disorder and Cocaine Use Disorder, sponsored by University of California, San Francisco.
NCT02028533 is a Phase 1 study of Opioid Use Disorder and Cocaine Use Disorder that has completed, run by University of California, San Francisco. The registered enrollment target is 30 participants, below the 4,656-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02028533, a Phase 1 study of Opioid Use Disorder and Cocaine Use Disorder, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a pilot feasibility study assessing the tolerability of chronic administration of intranasal oxytocin to patients receiving methadone at an opioid replacement clinic who are actively using cocaine.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Oxytocin
Study Locations (1)
California
- San Francisco General Hospital Opiate Treatment Outpatient Program - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2014-07 |
| Est. Completion | 2014-12 |
| Phase | Phase 1 |
What the finished NCT02028533 record still lists
NCT02028533 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 4,656-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (99% lower).
The record links to 2 conditions, with Opioid Use Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02028533 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT02028533 about?
NCT02028533 is a clinical study titled "Cocaine Opioid Oxytocin Option - Limited". This is a pilot feasibility study assessing the tolerability of chronic administration of intranasal oxytocin to patients receiving methadone at an opioid replacement clinic who are actively using cocaine.
What is the current status of trial NCT02028533?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2014-07. Estimated completion is 2014-12.
What conditions does trial NCT02028533 study?
This clinical trial studies the following conditions: Opioid Use Disorder, Cocaine Use Disorder.
What interventions are being tested in trial NCT02028533?
The interventions under investigation include: Placebo (DRUG), Oxytocin (DRUG).
Who is sponsoring clinical trial NCT02028533?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02028533 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Opioid Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02028533's enrollment target sits among peer trials
30 205th of 257 higher than 46 of 257 other Opioid Use Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Opioid Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Right Tools, Right Time, Right Place: Telehealth for Opioid Use Disorder in Vulnerable Settings
RECRUITING · Phase 1
-
Study to Assess the Use of Tezampanel for Opioid Withdrawal Syndrome in Treatment-Seeking Patients With Opioid Use Disorder
RECRUITING · Phase 1
-
Cannabis and Opioid Use Disorder
RECRUITING · Phase 1
-
Adjunctive Effects of Psilocybin and a Formulation of Buprenorphine
RECRUITING · Phase 1
-
A Bundled Intervention
RECRUITING · Phase 1
-
Evaluation of the Interactions of Cannabidiol (CBD) With Morphine
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia